OBJECTIVES: We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. BACKGROUND: Statin-induced side effects can interfere with therapy. Single nucleotide polymorphisms in cytochrome P450 enzymes impair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associated with simvastatin-induced myopathy with creatine kinase (CK) elevation. METHODS: The STRENGTH (Statin Response Examined by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety. Subjects (n = 509) were randomized to atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 10 mg followed by 80 mg, 80 mg, and 40 mg, respectively. We defined a composite adverse event (CAE) as discontinuation for any side effect, myalgia, or CK >3x upper limit of normal during follow-up. We sequenced CYP2D6, CYP2C8, CYP2C9, CYP3A4, and SLCO1B1 and tested 7 reduced function alleles for association with the CAE. RESULTS: The CAE occurred in 99 subjects (54 discontinuations, 49 myalgias, and 9 CK elevations). Sex was associated with CAE (percent female in CAE vs. no CAE groups, 66% vs. 50%, p < 0.01). SLCO1B1*5 was associated with CAE (percent with > or = 1 allele in CAE vs. no CAE groups, 37% vs. 25%, p = 0.03) and those with CAE with no significant CK elevation (p < or = 0.03). Furthermore, there was evidence for a gene-dose effect (percent with CAE in those with 0, 1, or 2 alleles: 19%, 27%, and 50%, trend p = 0.01). Finally, the CAE risk appeared to be greatest in those carriers assigned to simvastatin. CONCLUSIONS:SLCO1B1*5 genotype and female sex were associated mild statin-induced side effects. These findings expand the results of a recent genome-wide association study of statin myopathy with CK >3x normal to milder, statin-induced, muscle side effects.
RCT Entities:
OBJECTIVES: We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. BACKGROUND: Statin-induced side effects can interfere with therapy. Single nucleotide polymorphisms in cytochrome P450 enzymes impair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associated with simvastatin-induced myopathy with creatine kinase (CK) elevation. METHODS: The STRENGTH (Statin Response Examined by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety. Subjects (n = 509) were randomized to atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 10 mg followed by 80 mg, 80 mg, and 40 mg, respectively. We defined a composite adverse event (CAE) as discontinuation for any side effect, myalgia, or CK >3x upper limit of normal during follow-up. We sequenced CYP2D6, CYP2C8, CYP2C9, CYP3A4, and SLCO1B1 and tested 7 reduced function alleles for association with the CAE. RESULTS: The CAE occurred in 99 subjects (54 discontinuations, 49 myalgias, and 9 CK elevations). Sex was associated with CAE (percent female in CAE vs. no CAE groups, 66% vs. 50%, p < 0.01). SLCO1B1*5 was associated with CAE (percent with > or = 1 allele in CAE vs. no CAE groups, 37% vs. 25%, p = 0.03) and those with CAE with no significant CK elevation (p < or = 0.03). Furthermore, there was evidence for a gene-dose effect (percent with CAE in those with 0, 1, or 2 alleles: 19%, 27%, and 50%, trend p = 0.01). Finally, the CAE risk appeared to be greatest in those carriers assigned to simvastatin. CONCLUSIONS:SLCO1B1*5 genotype and female sex were associated mild statin-induced side effects. These findings expand the results of a recent genome-wide association study of statin myopathy with CK >3x normal to milder, statin-induced, muscle side effects.
Authors: T E Klein; J T Chang; M K Cho; K L Easton; R Fergerson; M Hewett; Z Lin; Y Liu; S Liu; D E Oliver; D L Rubin; F Shafa; J M Stuart; R B Altman Journal: Pharmacogenomics J Date: 2001 Impact factor: 3.550
Authors: C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes Journal: Lancet Date: 2005-09-27 Impact factor: 79.321
Authors: Marc A Pfeffer; Anthony Keech; Frank M Sacks; Stuart M Cobbe; Andrew Tonkin; Robert P Byington; Barry R Davis; Carola P Friedman; Eugene Braunwald Journal: Circulation Date: 2002-05-21 Impact factor: 29.690
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Deepak Voora; Svati H Shah; Carol R Reed; Jun Zhai; David R Crosslin; Chad Messer; Benjamin A Salisbury; Geoffrey S Ginsburg Journal: Circ Cardiovasc Genet Date: 2008-12-09
Authors: Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar Journal: Ann Med Date: 2020-08-24 Impact factor: 4.709
Authors: Otito F Iwuchukwu; QiPing Feng; Wei-Qi Wei; Lan Jiang; Min Jiang; Hua Xu; Joshua C Denny; Russell A Wilke; Ronald M Krauss; Dan M Roden; C Michael Stein Journal: Pharmacogenomics Date: 2014-11 Impact factor: 2.533
Authors: Sonal Singh; Susan Zieman; Alan S Go; Stephen P Fortmann; Nanette K Wenger; Jerome L Fleg; Barbara Radziszewska; Neil J Stone; Sophia Zoungas; Jerry H Gurwitz Journal: J Am Geriatr Soc Date: 2018-10-02 Impact factor: 5.562
Authors: Josephine H Li; Sunil Suchindran; Svati H Shah; William E Kraus; Geoffrey S Ginsburg; Deepak Voora Journal: Pharmacogenomics Date: 2015 Impact factor: 2.533
Authors: W-Q Wei; Q Feng; L Jiang; M S Waitara; O F Iwuchukwu; D M Roden; M Jiang; H Xu; R M Krauss; J I Rotter; D A Nickerson; R L Davis; R L Berg; P L Peissig; C A McCarty; R A Wilke; J C Denny Journal: Clin Pharmacol Ther Date: 2013-10-04 Impact factor: 6.875
Authors: Amy Webb; Audrey C Papp; Jonathan C Sanford; Kun Huang; Jeffrey D Parvin; Wolfgang Sadee Journal: Pharmacogenet Genomics Date: 2013-05 Impact factor: 2.089